Biotech’s near-term key catalysts
Important data reveals are expected from Madrigal, Arrowhead and Ascendis, with details from Biogen and Eisai due at a conference.
Big pharma’s key fourth-quarter data
Merck & Co and Novartis are set for important disclosures as Roche battles with Biogen and Eisai in Alzheimer’s.
T3D puts a bet on Alzheibetes
An unusual update at last month’s AAIC meeting puts the focus on a phase 2 readout next year, but time might be running out.
Medtech takes on pain
Attempts to treat pain with non-opioid drugs have ended in repeated failures – but device makers have met with greater success.
Go or no go? Bristol’s Tyk2 test
A green light from the FDA is expected for deucravacitinib, while Amylyx, Ferring and Oncopeptides head for panels.
